Published in Glycoconj J on May 01, 2006
Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur Biophys J (2007) 1.29
Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. J Biol Chem (2013) 0.91
Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion. Mol Membr Biol (2008) 0.86
The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol J (2006) 0.85
Function of membrane rafts in viral lifecycles and host cellular response. Biochem Res Int (2011) 0.82
Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. Antiviral Res (2008) 0.80
Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J (2012) 0.79
Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia. FASEB J (2008) 0.79
Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes. PLoS One (2010) 0.78
Early and late HIV-1 membrane fusion events are impaired by sphinganine lipidated peptides that target the fusion site. Biochem J (2014) 0.76
Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides. Bioorg Med Chem (2011) 0.76
Functional rafts in cell membranes. Nature (1997) 38.89
Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol (1998) 14.83
HIV entry and its inhibition. Cell (1998) 9.42
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res (1984) 3.67
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Ternary phase diagram of dipalmitoyl-PC/dilauroyl-PC/cholesterol: nanoscopic domain formation driven by cholesterol. Biophys J (2001) 3.35
HIV entry and tropism: the chemokine receptor connection. AIDS (1997) 3.32
Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep (2000) 3.23
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med (1997) 2.67
Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses (2001) 2.60
Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem (1998) 2.57
Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J Virol (1998) 2.46
Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc Natl Acad Sci U S A (1995) 2.46
Cholesterol depletion induces large scale domain segregation in living cell membranes. Proc Natl Acad Sci U S A (2001) 2.41
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (2001) 2.07
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol (2002) 1.81
Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol (2000) 1.67
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell (1997) 1.60
Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS (2002) 1.55
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol (2003) 1.30
Cell biology of virus entry. Cell (2000) 1.29
The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1998) 1.23
Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem (1998) 1.20
Evidence for the existence of ganglioside-enriched plasma membrane domains in human peripheral lymphocytes. J Lipid Res (1997) 1.16
A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope. AIDS Res Hum Retroviruses (1993) 1.10
An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS (2004) 0.93
CD4 segregates into specific detergent-resistant T-cell membrane microdomains. Tissue Antigens (1999) 0.92
Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconj J (2001) 0.90
Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol (1999) 0.88
Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion. Virology (2004) 0.87
Lipids in viral fusion. Methods Mol Biol (2002) 0.79
Entry of influenza virus into a glycosphingolipid-deficient mouse skin fibroblast cell line. Arch Virol (2001) 0.78
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry (2005) 1.52
HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem (2012) 1.48
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol (2008) 1.41
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol (2003) 1.30
Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A (2004) 1.22
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology (2002) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem (2009) 1.08
Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry (2003) 1.07
Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem (2007) 1.06
Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J Virol (2007) 1.06
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion. J Virol (2003) 1.03
Anticancer β-hairpin peptides: membrane-induced folding triggers activity. J Am Chem Soc (2012) 1.03
Multifunctional RNA nanoparticles. Nano Lett (2014) 1.03
Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol (2005) 1.01
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun (2007) 0.99
Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother (2009) 0.98
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol (2005) 0.97
A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells. Biochim Biophys Acta (2010) 0.97
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Biochemistry (2004) 0.96
Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci Rep (2005) 0.96
Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol (2010) 0.96
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release (2011) 0.96
Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry (2008) 0.95
An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS (2004) 0.93
Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry (2002) 0.93
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS (2006) 0.93
The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem (2004) 0.92
The role of glycosphingolipids in HIV signaling, entry and pathogenesis. Glycoconj J (2004) 0.92
Fluorescent lipid probes in the study of viral membrane fusion. Chem Phys Lipids (2002) 0.92
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine (2008) 0.91
In Silico, In Vitro, and In Vivo Studies Indicate the Potential Use of Bolaamphiphiles for Therapeutic siRNAs Delivery. Mol Ther Nucleic Acids (2013) 0.91
Mechanism of membrane permeation induced by synthetic β-hairpin peptides. Biophys J (2013) 0.90
Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res (2011) 0.89
Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatr Nephrol (2005) 0.88
Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral Res (2005) 0.88
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano (2014) 0.88
Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion. Virology (2004) 0.87
Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J (2011) 0.86
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion. J Virol (2004) 0.86
Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion. Mol Membr Biol (2008) 0.86
Activation of different split functionalities on re-association of RNA-DNA hybrids. Nat Nanotechnol (2013) 0.86
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J (2010) 0.86